Select Page

Gilde Healthcare sees increased coronavirus remote monitoring, home care need amid $450m fund close

Gilde Healthcare sees increased coronavirus remote monitoring, home care need amid $450m fund close


An increased need for remote monitoring and home care of patients due to the coronavirus outbreak is among focus areas for Gilde Healthcare following the $450m final close of its latest investment fund.

That total is almost double the total the firm collected for its predecessor fund in 2016, which reached its €250m hard cap.

The oversubscribed Gilde Healthcare V, a venture capital and growth capital fund, will target areas including digital health, medtech and therapeutics in Europe and North America, with a special attention for private healthcare companies enabling improved care at affordable cost.

Pieter van der Meer, managing partner of Gilde Healthcare, said, “The healthcare landscape in Europe and the US is changing rapidly, driven by the need for more patient centric care and more focus on value based care.

“With our new fund we will continue our strategy to invest in venture and growth stage companies developing novel solutions that enable better healthcare outcomes at reduced costs.

“An example is remote monitoring and home care of patients which is now more relevant than ever in the fight against COVID-19.”

Gilde Healthcare V was raised in a single close, and is backed by investors including Royal Philips and Rabo Corporate Investments, HANIEL, KfW Capital, BNP Paribas, Fortis Private Equity, Belgian Growth Fund, Danish Growth Fund and the European Investment Fund.

Recent Gilde Healthcare exits include the sale of infectious disease diagnostic platform STAT-Dx to Qiagen, the trade sale of Breath Therapeutics to Zambon Pharma and the NASDAQ listing of Axonics, focused on the treatment of overactive bladder.

Gilde Healthcare also has a strong track record with healthcare unicorns such as Ablynx, Ascendis Pharma and uniQure.

The Gilde Healthcare V fund will typically make equity investments in a single portfolio company of between $10m and $40m.

Last year the firm closed its most recent private equity-focused vehicle, Gilde Healthcare Services III, on €200m.

Copyright © 2020 AltAssets





Source link

About The Author

Leave a reply

Your email address will not be published. Required fields are marked *